Somil Mehta, Mirae Asset ShareKhan’s Head of Retail Research, just issued a fresh set of buy/sell signals for October 13, 2026. The move is driven by a mix of technical breakouts and momentum crossovers that suggest a bearish swing for three of India’s blue‑chip stocks while a single pharma name looks poised for upside.
Bank of India (BOI.NS) is slated for a sell at ₹134, with a stop at ₹137.50 and a target of ₹128. The weekly chart shows the stock breaking its ascending channel and forming a lower‑top/lower‑bottom structure below the 20‑ and 40‑period WEMA. On the daily, multiple rejections near the 20‑DEMA coincide with a resistance zone that had previously served as a strong support level, reinforcing the bearish outlook.
GAIL (GAIL.NS) is to be sold at ₹167‑168, with a stop at ₹172.20 and a target of ₹161. The weekly picture reveals a breakdown from a broad trading range, while the daily chart shows rejections at the 20‑ and 40‑DEMA and a dip below the 200‑DEMA. Momentum indicators are showing a negative cross‑over, adding weight to the sell thesis.
Dabur India (DABUR.NS) faces a sell recommendation at ₹374‑375, a stop at ₹387 and a target of ₹359. The weekly trend is a lower‑top/lower‑bottom pattern below the 200‑WEMA, and the daily chart displays multiple rejections from the 20‑ and 40‑DEMA, aligning with the upper Bollinger Band which acts as a key resistance. Negative momentum cross‑overs confirm the bearish stance.
Dr Reddy’s Laboratories (DRREDDY.NS) is the only buy in the mix, with a target range of ₹1229‑1230, a stop at ₹1185 and a higher target of ₹1280. The weekly chart shows a breakout above the 38.20% retracement from the previous swing high of ₹1387, staying above the 20‑ and 40‑WEMA. On the daily, a breakout of the 200‑DEMA and a critical resistance zone has produced a positive momentum cross‑over, signalling potential upside.
These recommendations come at a time of heightened volatility across Indian equities. Banking stocks have been under pressure, commodity producers are wrestling with weak demand signals, and the pharma sector remains a mixed bag. While the bearish signals on BOI, GAIL and DABUR reflect technical weakness, the bullish outlook for Dr Reddy’s is anchored in a clear breakout and momentum support.
Investors should keep an eye on the upcoming earnings calendar – Dr Reddy’s next report is due in July 2026 – and on any sector‑specific policy shifts that could alter the technical narratives. The short‑term focus will be on the support and resistance levels outlined above, while the long‑term view hinges on how these technical cues translate into fundamental shifts in earnings and market sentiment.